N eurons work hard. To keep the 86 billion neurons in the human brain working properly requires an adequate supply of blood, which is accomplished through a vast, well-regulated vascular network of arteries, arterioles, capillaries, venules and veins reaching approximately 400 miles (~644 km) in length 1,2 . Several cell types work in concert to regulate cerebral blood flow (CBF) and maintain blood-brain barrier (BBB) integrity. This assortment of cells, collectively called the neurovascular unit (NVU), is comprised of endothelial cells forming the inner layer of the vessel walls, mural cells along the vessels that help regulate vascular tone (pericytes and vascular smooth muscle cells; SMCs), astrocytes whose endfeet cover most of the vasculature, and neurons 1,2 . The NVU cellular composition varies along the vascular tree, with rubber band-like SMCs wrapping vessels at the artery and arteriole levels, pericytes along capillaries, and 'stellate' SMCs along venules 3 (Fig. 1a) .
Pathways regulating CBF along the vascular tree. The NVU of the mammalian brain is functionally integrated to regulate CBF responses to neuronal stimulation in a process called neurovascular coupling or functional hyperemia 1, 2 , which ensures a rapid increase in CBF and oxygen delivery to activated brain regions. Mural cells can depolarize and contract, or hyperpolarize and relax, in response to different stimuli, to either constrict or dilate blood vessels, respectively, which in turn decreases or increases blood flow. SMCs regulate arteriolar and arterial vessel diameters 1 . Most in vivo rodent studies in the brain and retina, as well as studies using cortical and cerebellar slices and retinal explants, suggest that pericytes regulate blood flow at the capillary level [13] [14] [15] [16] [17] [18] [19] [20] . However, this has not been confirmed by some in vivo studies in the mouse cortex 21, 22 , leaving this subject still as a matter of controversy. An exact explanation for these conflicting reports remains unclear at present, but could reflect technical challenges or underlying properties of the studied models that should be clarified by future studies. As pointed out in a recent review 1 , the evidence to date also does not rule out a role of capillaries (and pericytes) in the retrograde propagation of intramural vascular signals from the capillary level upstream 1, 23, 24 . Given that the vast majority of brain vasculature is composed of capillaries (~90% in mouse cortex) 13, 25 , capillaries and pericytes are well positioned to regulate CBF throughout the brain parenchyma. Figure 2 illustrates key cellular and molecular pathways regulating CBF.
Briefly, neurons signal the vasculature through transmitters ATP and adenosine, which act on their receptors-purinergic P2X and P2Y for ATP (also expressed on other CNS cell types 7, 11 ) and adenosine A 2A for adenosine-on SMCs and pericytes, causing depolarization and cell contraction that reduces blood flow, or hyperpolarization and cell relaxation that increases blood flow, as shown in vivo in cortex and retina and ex vivo in cortical slices and whole-mount retina 2, 13, 26 . Noradrenaline contracts SMCs ex vivo in isolated retina and in vivo in cortical arterioles 23 and contracts pericytes ex vivo in rat cerebellar slices and isolated retina 14 , whereas neuropeptide Y contracts cortical arterioles in vivo 27 . Neuronal nitric oxide (NO) can hyperpolarize and relax SMCs and pericytes, increasing blood flow in vivo and ex vivo 2, 15, 20 . Although it has been initially suggested that NO can act by blocking 20-hydroxyeicosatetraenoic acid (20-HETE) production, this mechanism may play a more important role in autoregulation of vascular tone than neurovascular coupling 28 . In contrast, a recent study suggested that dilation of arterioles depends on NMDA-receptor activation and Ca 2+ -dependent NO generation by interneurons, whereas the dilation of capillary pericytes in mouse cortex is mediated by local Ca 2+ elevations in glial processes and endfeet along capillaries 16 , although regional differences may exist [15] [16] [17] 20, 29 . These findings indicate that different signaling cascades regulate CBF at the capillary and , which acts on various K + and Ca 2+ channels to alter pericyte and SMCs tone, leading to alterations in blood flow, as shown in brain and retina in vivo 2,29 (Fig. 2 ). Astrocytes also respond to neuronal ATP through P2X or P2Y receptors by increasing intracellular calcium concentration ([Ca 2+ ]; similarly to microglia and oligodendrocytes 7, 11 ), as shown in live and whole-mount retina 26 , which triggers production of arachidonic acid (AA) and its vasoactive metabolites (20-HETE; prostaglandin E2, PGE2; and epoxyeicosatetraenoic acids, EETs), as shown in vivo in cortex and retina and ex vivo in cortical and cerebellar slices and retinal explants 2, 15, 16, 29 , as well as secretion of K + . Mural cells generate 20-HETE from AA, causing cell depolarization and blood flow reduction, while PGE2 hyperpolarizes SMCs and pericytes (via PGE2 receptor EP4, EP4R), increasing vessel diameter, as shown in vivo in cortex and retina and ex vivo in cortical and cerebellar slices and retinal explants 2, 15, 16, 29 . The role of astrocytes in CBF regulation has been, however, a matter of controversy, stemming from conflicting data as to whether astrocyte [Ca 2+ ] can increase in response to stimulus, and whether any [Ca 2+ ] increase can occur rapidly enough to influence neurovascular coupling 29 (Fig. 2 ). Additional studies are needed to resolve this controversy.
Endothelial cells respond to acetylcholine (ACh) from the blood stream via muscarinic ACh receptors 30, 31 and blood flow shear stress to generate NO 23 , which increases blood flow by relaxing pericytes and SMCs, as described above. ACh also causes NO-independent endothelial hyperpolarization 23 . Shear stress triggers production of AA and AA-derived metabolites (EETs; prostacyclin, PGI2), which act on SMCs to increase blood flow 23 . Extracellular [K + ] elevations can hyperpolarize endothelium at both the capillary and arteriole level, which can propagate in a retrograde direction via gap junctions shared between endothelial cells and endothelial-mural cell junctions, leading to relaxation and dilation of upstream vasculature to increase blood flow 1, 2, 23 . These endothelial pathways have been described ex vivo in various rodent aortic and brain arteriole ring preparations, and in vivo in cortex and cerebellum, but further validation studies in brain are needed. Expression of all major receptors, ion channels, and other key proteins in SMCs, pericytes, endothelial cells, and astrocytes contributing to CBF regulation, as ] increase triggers production of AA and its metabolites (PGE2, through PGE2 receptor EP4, EP4R; 20-HETE; epoxyeicosatetraenoic acids, EETs) that act on SMCs and pericytes to regulate blood flow. Alternatively, neurons may release AA to be further metabolized by astrocytes, indicated by dashed line. Endothelialmural cells crosstalk: ACh released from neurons or blood-derived ACh act on endothelial muscarinic ACh receptors (MRs) to increase endothelial NO production, causing hyperpolarization and relaxation of mural cells (yellow), which increases blood flow. Shear stress can also increase NO endothelial production, as well as production of AA, EETs, and prostacyclin (PGI2), which hyperpolarize and relax SMCs, increasing arteriolar blood flow. ACh or an increase in extracellular [K + ] can activate K IR or calcium-activated K + (K Ca ) channels on endothelial cells, leading to endothelial hyperpolarization that can propagate via gap junctions (GJs) between endothelial cells in a retrograde direction to increase blood flow. Altogether these findings are informed from various CNS regions and from both in vivo and in vitro studies.
Pathways regulating BBB integrity along the vascular tree.
Formation and maintenance of the BBB is accomplished through expression of tight junctions (for example, claudins, occludin, zona occludens) and adherens junctions (for example, vascular endothelial (VE)-cadherin, platelet endothelial cell adhesion molecule or PECAM-1, connexins) connecting neighboring endothelial cells, as well as the paucity of transendothelial bulk-flow transcytosis 4 . Gap junctions between endothelial cells, pericytes, and astrocytes contribute to cerebrovascular integrity. Upholding endothelial barrier is essential for the specialized transport properties and functions of BBB, as reviewed elsewhere 4 . Figure 3 summarizes key cellular and molecular pathways underlying BBB establishment and maintenance. Studies using pericyte-deficient murine models with reduced endothelial-derived platelet-derived growth factor-BB (PDGF-BB) bioavailability or deficient PDGF receptor-β (PDGFRβ ) signaling in pericytes have suggested that pericytes regulate BBB formation and maintenance at the level of brain capillaries 5, [32] [33] [34] [35] . PDGF-BB is a ligand for PDGFRβ on pericytes, which controls pericyte survival, proliferation, and migration [32] [33] [34] [35] [36] (Fig. 3 ). Endothelial-secreted Notch ligands signal, via Notch3 receptor in pericytes, to promote pericyte survival 5 . Similarly, pericyte-derived Notch ligands bind to endothelial Notch1 receptor, which promotes N-cadherin synthesis, stabilizing BBB 5 . Vascular endothelial growth factor-A (VEGF-A) signals VEGF receptor-2 (VEGFR2) in capillary endothelium, reinforcing cell survival 5 . Transforming growth factor-β (TGFβ )-and TGFβ receptor-2 (TGFβ R2)-signaling between pericytes and endothelial cells regulates endothelial proliferation and differentiation and pericytes proliferation and migration 5 (Fig. 3 ).
Ephrin type B receptor 2 (EphB2), expressed by arterial endothelial cells, regulates SMC recruitment to the developing vessels contributing to cerebrovascular integrity, which is indirectly indicative of BBB stability 4, 37 . Loss of EphB2 disrupts mural cell coverage, causing BBB breakdown 37 . Ablation of astrocytic laminin leads to BBB breakdown 38 . Apolipoprotein E (APOE) isoforms, secreted by astrocytes, regulate BBB integrity by signaling the low-density lipoprotein receptor-related protein-1 (LRP1) on pericytes 39 . Additionally, neuron-secreted Wnt, a ligand of the frizzled (FZD) receptor on endothelium, promotes endothelial cell differentiation during brain vasculogenesis 40, 41 .
Expression of all major receptors and key proteins in endothelial cells, pericytes, SMCs, and astrocytes regulating BBB integrity, as shown in Fig. 3 , has been supported by recent single-cell RNA-seq Platelet-derived growth factor-BB (PDGF-BB) binds to PDGFRβ on pericytes, causing pericyte survival, proliferation, and migration. Vascular endothelial growth factor-A (VEGFA) binds to endothelial VEGF receptor-2 (VEGFR2) mediating endothelial survival. Pericyte-derived notch ligands bind to endothelial Notch1 receptor, which mediates BBB stability, as does endothelial sphingosine-1 phosphate (S1P). Transforming growth factor-β (TGFβ ) and TGFβ receptor-2 (TGFβ R2) signaling occurs bidirectionally between pericytes and endothelial cells. Pericyte-secreted angiopoietin-1 (Angpt1) binds Tie2 receptors on endothelial cells to promote proliferation. Astrocyte-endothelial cells crosstalk: astrocyte-secreted APOE2 and APOE3, in contrast to APOE4, suppress the pro-inflammatory signaling cyclophilin A-NF-κ B-matrix metalloproteinase-9 (MMP9) pathway in pericytes to maintain BBB stability. Similarly, astrocyte-produced laminin maintains BBB stability. Astrocyte-secreted sonic hedgehog (Shh) interacts with patched-1 (PTCH1) at the endothelium to further promote BBB stability. SMC-endothelial cells crosstalk: ephrin B2 (EphB2) on the endothelium promotes BBB stability. PDGF-BB binds PDGFRβ on SMCs to promote survival and migration. Endothelial-secreted jagged-1 (Jag-1) binds Notch3 to promote SMC maturation and survival. Neuron-endothelial cells crosstalk: neuron-secreted Wnt is a ligand of frizzled (FZD) at the endothelium that promotes endothelial cell differentiation.
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NATure NeurOscieNce analysis of the brain vasculature in murine models 7 . Besides contributing to BBB formation, these pathways continue to play an important role in BBB maintenance in the adult and aging brain.
Gap between basic, translational, and human studies of the brain vasculature. The molecular and cellular mechanisms regulating CBF and BBB integrity, as discussed in the first half of this Review, have been extensively examined in animal models, generating important basic physiological data. However, these mechanisms have not been studied in great detail in models of neurodegenerative diseases that show early neurovascular dysfunction 6 , nor in humans with early CBF and BBB deficits that are consistently observed in different neurodegenerative diseases 2, 4, 6, [42] [43] [44] [45] . Whether investigation of the pathways and molecular makeup of the human brain vasculature can reproduce findings in animal models remains unclear, illustrating a major gap between animal models and human studies. Nevertheless, knowledge from animal studies offers a roadmap to examine the link between neurovascular dysfunction and neurodegeneration in humans. Neurovascular dysfunction is increasingly recognized in AD 1,2,4,42-48 , besides classical pathological hallmarks of the disease including amyloid-β (Aβ ) plaques, hyperphosphorylated tau neurofibrillary tangles, and neuronal loss 8 . Neuropathological studies show that cerebrovascular pathology contributes to dementia and clinically diagnosed AD 46 and lowers the threshold for dementia due to AD 47 . Similarly, vascular risk factors also lower the threshold and act synergistically with the Aβ burden to promote cognitive decline 49 . Neurovascular dysfunction is also seen as an early event in AD, influenced by genetic, lifestyle, and environmental factors, as demonstrated by vascular biomarkers studies 42, 44, 45, 50 and discussed in sections to follow.
In addition to AD, brain vasculature has been implicated in the pathogenesis of frontotemporal dementia, Parkinson's disease (PD), Huntington's disease (HD), amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), and other neurodegenerative conditions, such as HIV-induced neurocognitive disorder and chronic traumatic encephalopathy 1, 5, 45 . Here we focus on AD because more is known about neurovascular dysfunction in this disease than in other neurodegenerative disorders, but we also discuss the emerging role of neurovascular dysfunction in PD, HD, ALS, and MS. We concentrate on CBF and BBB neuroimaging biomarkers that have advanced the field in recent years establishing early role of brain vasculature in multiple neurodegenerative disorders.
Cerebral blood flow in Alzheimer's disease. CBF reductions, impaired cerebrovascular reactivity, and impaired hemodynamic responses are increasingly recognized in early stages of AD and across the normal aging-mild cognitive impairment (MCI)-AD spectrum (Table 1) . However, no evidence to date shows that CBF deficits are causal to AD. Below, we examine studies showing that CBF is a useful biomarker in preclinical AD.
CBF reductions.
Early studies found that individuals with greater CBF velocity, as shown by transcranial Doppler measurements in the middle cerebral artery, are less likely to develop dementia or hippocampal and amygdalar atrophy 51 . Similarly, individuals with MCI or early AD develop early CBF reductions in the posterior cingulate gyrus and precuneus, as shown by arterial spin labeling (ASL) MRI 2, 43, [52] [53] [54] . Progression from MCI to AD is associated with more global [55] [56] [57] [58] [59] [60] and severe (up to 40%) CBF reductions 61, 62 , which includes other CNS regions besides the posterior cingulate gyrus and precuneus, such as bilateral parietotemporal, frontal and occipital cortex, parahippocampal gyrus, hippocampus, and entorhinal cortex ( Table 1) . Studies using two-dimensional phase-contrast MRI confirmed CBF reductions in MCI 63 and full blown AD 64 .
A large-cohort longitudinal study from the Alzheimer's Disease Neuroimaging Initiative database suggested that changes in vascular biomarkers (for example, cerebrospinal fluid (CSF) heart-type fatty acid-binding protein, cortisol, and apolipoprotein A, all associated with cardiovascular disorders 42 ) and decreased CBF by twodimensional (2D) ASL occur before detectable changes in classical Aβ and tau CSF AD biomarkers 42 . Ideally, the CBF findings in this study 42 should be confirmed using more sensitive methods, such as those that use contrast agents (for example, dynamic susceptibility contrast or dynamic contrast-enhanced (DCE) perfusion) to achieve a better signal-to-noise ratio compared to ASL, which is less optimal and noisy. Reduced CBF in parietotemporal cortex and basal ganglia in MCI was also shown to occur before brain atrophy by dynamic susceptibility contrast MRI studies 65 . ASL imaging and Pittsburgh compound B amyloid positron emission tomography (PET) imaging revealed widespread and Aβ -independent CBF reductions in cognitively normal APOE4 carriers with the strongest genetic risk for AD 66 . An [ 15 O]-labeled water-PET longitudinal study showed that a widespread decline of CBF occurs over time in cognitively normal APOE4 carriers 67 . More longitudinal studies are needed to better understand the relationship between CBF and Aβ and tau pathological changes. Impaired cerebrovascular reactivity. Impaired cerebrovascular reactivity, reflecting diminished vasodilation of cerebral vessels in response to a CO 2 inhalation challenge, was found early in AD compared to cognitively normal controls using transcranial Doppler 68 and the blood oxygenation level dependent (BOLD) functional MRI (fMRI) 69 . However, the evidence that this is etiologic is lacking, and while it is possible that these effects could also be downstream to Aβ -mediated vasculopathy, neither of these two studies investigated the presence of cerebral amyloid angiopathy (CAA). CAA is characterized by deposition of Aβ in the wall of small and mid-sized cerebral and leptomeningeal arteries, veins, and cerebral capillaries, and is related to AD 70 . Impaired cerebral blood vessel reactivity to CO 2 has also been shown in the hippocampus of young, nondemented APOE4 carriers compared to noncarriers by BOLD-fMRI in response to a memory task 71 , and by reduced CBF velocity in the middle cerebral artery using transcranial Doppler 72 (Table 1) . Impaired neurovascular coupling. BOLD-fMRI provides a measure of neurovascular coupling by detecting an increase in blood oxygen delivery and CBF in response to neuronal stimulation 43 . The physiological basis of the BOLD signal has not been fully elucidated and current models include contributions from different hemodynamic and blood parameters 43 . Most fMRI studies treat the BOLD response as an indirect qualitative measure of neuronal activity and interpret BOLD signal differences as changes in neuronal activity. However, the BOLD signal reflects local changes in deoxyhemoglobin content, which in turn exhibits an intricate dependence on changes in CBF, cerebral blood volume, and the cerebral metabolic rate of oxygen consumption (CMRO 2 ). Factors that disturb the connection between CBF and CMRO 2 (for example, altered cerebrovascular structure, reduced blood vessel elasticity, atherosclerosis, reduced resting-state CBF, decreased resting CMRO 2 , reduced vascular reactivity to chemical modulators) may therefore substantially change the BOLD signal during aging and AD, even when neuronal activity is unchanged, which should be taken into account in data interpretation 43 . Reduced CBF response to visual stimuli and memory encoding tasks were detected in the hippocampus, parahippocampal gyrus, precuneus, and posterior cingulate cortex in MCI patients 73 and in the hippocampus in AD patients 73, 74 . Changes in the hemodynamic response in the visual cortex were also found in patients with CAA 75 that associate with cerebrovascular dysfunction 45 . Alterations in BOLD signal activity during AD progression appear to be regionally specific and depend on the nature of (Table 1 ). However, two important caveats have limited the application and interpretation of BOLD studies in AD, including head motion artifacts and the often-limited ability of subjects with neurodegenerative diseases to perform tasks.
Animal studies. Most animal CBF studies have been done in transgenic AD APP models of Aβ amyloidosis. These studies have shown that Aβ has vasoactive and vasculotoxic effects on brain vessels, as recently reviewed 2 . Briefly, Aβ vasoactive effects were shown on cerebral blood vessels both in vitro and in vivo in transgenic mouse models overexpressing human APP mutations 1,2 , including impaired CBF responses to vasodilators 76 and dysfunctional neurovascular coupling 77 . Thus, preventing Aβ deposition may clearly abolish Aβ -dependent effects on CBF reductions and dysregulation. A recent study in APP mice expressing human Swedish, Dutch, and Iowa mutations has demonstrated, however, that counteracting the harmful effects of Aβ after vascular depositions is not effective in reversing the neurovascular dysfunction, owing to the mural cell damage that is caused by aging and massive Aβ deposition 78 . Several studies report that CBF dysregulation develops early in experimental models of mural cell or endothelial dysfunction, which can lead to neuronal dysfunction and loss, independent of Aβ , as recently reviewed 2 . For instance, pericyte-deficient mutant mice develop early CBF reductions in gray 33 and white 79 matter in the absence of Aβ pathology, and they develop aberrant CBF responses in the presence of initially normal neuronal activity, endothelial vasodilation, and astrocyte coverage of the blood vessels 13 . Thus, CBF reductions and dysregulation in mouse models can develop independent of Aβ and precede neuronal dysfunction, similarly to what has been suggested by human studies (Table 1 ). In humanized APOE4 transgenic mice, early CBF reductions precede neuronal dysfunction independently of Aβ 39,80 , as it does in human APOE4 carriers, as discussed above. 
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Blood-brain barrier in Alzheimer's disease
In parallel to early CBF changes, BBB breakdown and dysfunction have been shown in early stages during AD pathophysiological progression (Table 2 ). Below, we examine studies indicating that BBB is a useful biomarker in preclinical AD.
BBB permeability. Blood-to-brain leakage of an intravenously administered gadolinium-based contrast agent, as measured with DCE-MRI and quantified with the Patlak analysis, has recently enabled detection of subtle, regional changes in BBB permeability during the normal aging-MCI-AD spectrum 43, 44 . These studies have shown an increase in BBB permeability in the hippocampus and its CA1 and dentate gyrus subfields during normal aging 44 , which is further accelerated in individuals with MCI before brain atrophy or detectable changes in Aβ and tau CSF biomarkers 44 . Individuals with MCI and early AD develop, with disease progression, increased BBB permeability in other brain regions including cortex, deep gray matter, and white matter, all before dementia 59, 81, 82 . During MCI, the increased BBB permeability correlated with pericyte injury, as measured via the CSF PDGFRβ pericyte biomarker, further supporting the presence of early BBB breakdown and capillary damage 44 . Interestingly, vascular risk factors such as atherosclerosis, cardiac arrhythmia, and coronary disease did not influence BBB permeability 59 , suggesting that BBB breakdown during preclinical and early AD is not related to concomitant vascular conditions, but is rather an early independent biomarker contributing to AD pathophysiology. Future longitudinal studies are needed to precisely define the role of BBB breakdown in cognitive impairment and loss of structural and functional connectivity during AD progression and to elucidate the cellular and molecular mechanisms through which it promotes AD pathology.
Microbleeds. Microbleeds, caused by blood leakage into brain parenchyma from damaged blood vessels due to loss of BBB integrity, can be visualized by T2* MRI sequences as hyposignals reflecting perivascular accumulation of blood-derived hemosiderin deposits 43 . Several studies indicate the appearance of microbleeds during normal aging [83] [84] [85] [86] [87] [88] , which is further accelerated in individuals with MCI [83] [84] [85] 89 , early AD 83,85,86,88-90 , and AD 85 . Microbleeds reflect cerebral small-vessel disease, which is observed in approximately 50% of all dementia cases worldwide 48, 91 and is associated with worse cognitive performance 85 and white matter hyperintensities 87, 88 . APOE4 status accelerates microbleed prevalence in a majority of studies [86] [87] [88] , but not all 84 . However, at present there is no evidence that microbleeds are etiologically important in causing the AD pathology of plaques and tangles, and/or that they cause AD. Microbleed etiology and topography are related, with CAA causing lobar microbleeds in AD and hypertensive arteriopathy causing deep infratentorial microbleeds 91 . Hypertension positively associates with microbleed size and prevalence 85, 87 , particularly in infratentorial regions, whereas other vascular risk factors such as diabetes and hyperlipidemia do not associate with microbleeds 86 . Some studies indicate that microbleeds predominate in deep infratentorial regions during early preclinical AD and MCI stages 84, 87 , supporting the view that they may precede amyloid pathology, as determined by the lack of difference in CSF Aβ 42 in MCI subjects with and without microbleeds 84 , but they are later seen in lobar regions 85, 86, 88, 90 , reflecting CAA etiology during AD progression ( Table 2 ). CAA further contributes to BBB breakdown, infarcts, white matter changes, and cognitive impairment, leading the detection of dementia earlier 92 . Of note, studies using different magnetic field strengths indicate that the 7T magnet has approximately three times greater ability to detect smaller microbleeds compared to the 3T magnet 89 ; this has implications for future research to determine the true quantity and size of microbleeds that appear throughout the normal aging-MCI-AD spectrum.
Glucose transport. Numerous 18 F-fluoro-2-deoxyglucose (FDG)-PET studies show decreased glucose brain uptake in early stages of AD before amyloid and tau changes are detectable by amyloid-PET and/or Aβ 42 and phosphorylated-tau CSF analysis, and/or before detectable brain atrophy [93] [94] [95] [96] [97] [98] . Cognitively normal individuals with increased genetic risk for AD, such as PSEN1 mutation carriers 99, 100 and APOE4 carriers 96 , or people with positive AD maternal history 94 , also display decreased FDG brain uptake as an initial pathophysiological event. Longitudinal studies indicate that FDG brain uptake is further diminished in AD in individuals that converted into AD either from the cognitively unimpaired stage or from MCI 93, 97, [101] [102] [103] . These reductions in brain uptake of glucose in AD patients are thought to reflect pathological hypometabolism resulting from neurodegeneration 8, 104 . However, there is evidence from animal models that brain uptake of 2-deoxyglucose depends on the BBB glucose transporter-1 (GLUT1). In particular, deletion of a single Slc2a1 allele encoding GLUT1 at the BBB in mice diminishes 14 C-2-deoxyglucose brain uptake, followed by BBB breakdown, CBF reductions and dysregulation, capillary rarefaction, and eventually neuronal dysfunction and loss 105 . In humans, a few kinetic FDG-PET studies have demonstrated reductions in FDG BBB transport in AD [106] [107] [108] . These reductions in BBB transport may be explained by the fact that the reduced expression of GLUT1 was found in the brain capillaries of AD patients in postmortem studies [109] [110] [111] [112] (Table 2) . Thus, in our opinion, reduced FDG-PET does not reflect only glucose neuronal hypometabolism but can also reflect reduced transport of glucose across the BBB. Future studies in animal models and humans using glucose, FDG, and glucose analogs that track only BBB transport (for example, 3-O-[ 11 C]-methyl glucose) 113 , and-in addition to PET-more sensitive analytical methods such as nuclear magnetic resonance spectroscopy, should further explore brain glucose transport and metabolism in AD and the therapeutic potential of GLUT1 BBB transporter.
Diminished P-glycoprotein function. P-glycoprotein is an active efflux transporter expressed at the BBB luminal endothelium 4 . Laboratory studies indicate that Aβ is cleared from brain-toblood via abluminal LRP1-dependent efflux followed by luminal P-glycoprotein transport 4, 114 . Individuals with early AD develop widespread reductions in P-glycoprotein BBB function in the parietotemporal, frontal, occipital, and cingulate cortices, as well as in the hippocampus, as shown using PET with the radiolabeled P-glycoprotein substrate 11 C-verapamil 115, 116 . Diminished P-glycoprotein BBB function occurred independently of reduced CBF 115 and before brain atrophy 116 . In addition to P-glycoprotein, other BBB transporter changes including increased levels of the receptor for advanced glycation end products (RAGE), a major Aβ influx transporter at the BBB; and decreased levels of LRP1, a major Aβ efflux transporter at the BBB, were found in cerebral blood vessels of AD patients 45 .
Animal studies. Consistent with human studies, studies in different models relevant to AD pathophysiology also indicate the presence of BBB breakdown and dysfunction. This topic has been comprehensively reviewed recently 6 , and will not be examined in great detail here. Briefly, animal studies using transgenic models with various mutations in human APP gene have demonstrated perivascular accumulation of blood-derived proteins (for example, fibrinogen, immunoglobulin G (IgG), albumin), vascular leakage of circulating exogenous tracers, loss of tight junction proteins, loss of pericyte coverage, pericyte and endothelial degeneration, and microbleeds, altogether indicating BBB breakdown 6, 117 . Although most studies did not examine the time course of BBB changes in relation to other brain pathologies, those that did indicated that BBB breakdown occurs early before amyloid accumulation, behavioral deficits, or brain degenerative changes 6 Different PSEN1 models (for example, PSEN1 knockouts and PSEN1 mutations driven by neuronal promoters) exhibit microbleeds and endothelial degeneration indicative of BBB breakdown 122, 123 , occurring before brain Aβ and CAA pathology 122 . AD models with tau mutations show also BBB leakage of exogenous tracers, IgG deposits, microbleeds, and leukocyte infiltration despite no evidence of brain Aβ or CAA accumulation 124 . Finally, 
cBF and BBB in other neurodegenerative disorders
Early CBF and BBB changes are also found in other neurodegenerative disorders including PD, HD, MS, and ALS (Table 3) .
CBF reductions.
Decreased CBF was found throughout the cortical mantles and precuneus in PD patients with a range of motor and cognitive impairments using ASL-MRI 126 . A recent study showed that CBF reductions were also detectable in nondemented patients with PD 127 , suggesting that perfusion abnormalities may be an early biomarker upstream of cognitive impairment and neurodegeneration. Similarly, perfusion deficits were found in the cortex in early HD before cognitive dysfunction 128 . Using contrast MRI, early CBF reductions were detected in white matter lesions and in normally appearing white matter in relapsing-remitting MS patients with and without cognitive impairment 129, 130 . ALS patients also develop early perfusion deficits in frontoparietal cortex, subcortical gray matter, and white matter in the absence of cognitive decline 131 , which is independent of brain atrophy 132 .
Impaired cerebrovascular reactivity. Global impaired vasodilation of cerebral vessels in response to CO 2 has been shown in PD using transcranial Doppler 133 and BOLD-fMRI 134 . Decreased cerebrovascular reactivity was also reported in MS 135 . Whether altered cerebrovascular reactivity occurs before motor and cognitive impairments remains, however, unknown.
BBB permeability. DCE-MRI studies indicated increased regional BBB permeability (i.e., K trans values) in the basal ganglia in PD 136 , caudate nucleus in HD 137 , and white matter in MS 44, 129, [138] [139] [140] before cognitive decline 44, 136, 137, 139 . Increased K trans BBB permeability values indicated perivascular lesion growth in MS with minimal motor symptoms 139 , suggesting loss of BBB integrity could be an early event driving MS pathophysiology. occurring before cognitive decline 141, 144 . However, it remains unclear whether microbleeds precede motor symptoms in PD and ALS. Moreover, the prevalence and regional distribution of microbleeds in HD and MS is presently unknown.
Diminished P-glycoprotein function. [ 11 C]-verapamil-PET scans indicated diminished P-glycoprotein efflux transport function at the BBB in the midbrain in PD subjects with no cognitive impairment 145 . Whether or not P-glycoprotein or other BBB transporters play a role in HD, ALS, or MS is currently elusive.
CNS leukocyte infiltration.
PET studies using a radiolabeled matrix metalloproteinase inhibitor ligand indicated increased matrix metalloproteinase activity in MS lesions, suggesting enhanced leukocyte infiltration across the BBB into the brain of cognitively normal MS patients 146 .
Animal studies. CBF and BBB dysfunctions have also been shown in animal models of PD, HD, ALS, and MS, as recently examined elsewhere 147, 148 .
Vascular pathways to neurodegeneration. The first hypothetical model of in vivo AD dynamic biomarkers, often called the Jack model, was proposed in 2010 and updated in 2013 to include interim evidence and present intersubject variability in cognitive impairments 8 . This model was intended to summarize literature showing temporal evolution of in vivo AD biomarkers relative to each other and to the onset and progression of clinical symptoms. This initial model, however, did not include currently available evidence that vascular dysfunction contributes to AD pathophysiology in a stubstantial way 1 . Therefore, it is time now to update the hypothetical biomarkers model of AD to include the impact of cerebral Hypothetical model of AD biomarker changes illustrating that early CBF and BBB biomarkers and vascular dysfunction may contribute to initial stages of AD pathophysiological progression from no cognitive impairment (NCI) to MCI to AD, which is followed by cerebrospinal fluid and brain changes in Aβ , amyloid, and tau biomarkers. All biomarker curves converge at the point of maximum abnormality. The horizontal axis of disease progression is expressed as time. Cognitive response is illustrated as a zone (blue filled area) with low and high-risk borders. Subjects with high risk of AD-related cognitive impairment are shown with a cognitive response curve that is shifted to the left. In contrast, the cognitive response curve is shifted to the right in subjects with a protective genetic profile, high cognitive reserve, and the absence of comorbid brain pathologies. Fig. 5 | commonality of an early involvement of brain vasculature in different neurodegenerative disorders. a,b, Region-specific brain vascular dysfunction including CBF shortfalls (reductions and dysregulation) and/or BBB breakdown (increased vascular permeability and transporter dysfunction) is a common pathway seen early in multiple neurodegenerative disorders, including AD, PD, HD, ALS, and MS. See Tables 1, 2, and 3 for details. Specifically, some studies suggest that vascular dysfunction (CBF and/or BBB) in the hippocampus, gray matter, and entorhinal cortex in AD may precede dementia, brain atrophy, and/or detectable Aβ and tau biomarker changes. Similarly, vascular dysfunction in the white matter and corpus callosum in MS, basal ganglia (the caudate nucleus, thalamus, putamen, globus pallidus, and substantia nigra) in PD and HD, spinal cord white matter pyramidal tract in MS, and motor cortex and spinal cord in ALS are found by some studies in early stages of these disorders before progression of neurological symptoms including motor deficits. blood vessels on AD pathophysiology, as previously suggested 42, 149 . Figure 4 presents an updated, revised model of AD biomarkers to show the role of brain vasculature and early changes in CBF and BBB biomarkers in AD that, according to some studies (see Tables 1  and 2) , are altered before cognitive decline, brain atrophy, neurodegeneration, and/or amyloid and tau biomarker abnormalities. The sigmoid shape of the vascular curve reflects growing evidence obtained from imaging, biofluid, and postmortem tissue studies indicating an initial acceleration followed by deceleration of brain vascular changes, which do not plateau, similarly to those shown for the other biomarkers. However, future longitudinal studies may warrant amendment of the proposed trajectories of the vascular curve, as well as of the other biomarkers' curves and/or their order of their respective appearance. As discussed above, AD can be viewed as a model for other neurodegenerative diseases that are beginning to reveal notable vascular contributions to disease pathophysiology such as PD, HD, ALS, and MS (Table 3 ). Figure 5 illustrates the commonalities of vascular dysfunction across neurodegenerative diseases, focusing on specific regions where CBF shortfalls and BBB dysfunction are evident during early stages of each disease.
conclusions and future directions
An emerging role of brain vasculature in the pathogenesis of human neurodegenerative diseases, particularly AD, has led to increasingly recognized importance of healthy blood vessels for normal brain functioning. A recent single-cell transcriptomics approach to examining vascular zonation along the A-V axis in mouse models is a huge conceptual advancement 7 , providing important insights to biological processes at different levels of the vascular tree and BBB. The single-cell RNA-seq approach holds great promise in helping us understand the cellular and molecular basis of CBF and BBB dysfunction in models of neurodegenerative disorders and AD, and by extension in humans with these disorders. While the molecular atlas of cerebral blood vessels and BBB is being elucidated in animal models, we lack the molecular definition of human brain vasculature, BBB, and perhaps NVU, to generate an atlas of blood vessels in the human brain during health and disease. Comparative knowledge of the molecular makeup between humans and animals is essential to bridge this translational gap and for future studies to take advantage of discoveries in animal models. This has the potential to reveal why regional changes in the brain vasculature may lead to disease-specific neurological phenotypes in different neurodegenerative diseases and may inform about gene networks and upstream regulators driving the link between cerebrovascular dysfunction and neurodegeneration.
Neuroimaging holds the potential to further examine the regional vascular pathophysiology in the living human brain. Further advances are needed, such as development of novel neuroimaging modalities for biomarkers of different vascular cell types including SMCs, pericytes and endothelial cells, markers of vascular zonation, and/or molecular pathways in blood vessels. For example, PET imaging with radiolabeled matrix metalloproteinase inhibitors examines in vivo leukocyte infiltration across the human BBB in multiple sclerosis, which can be applied to AD and other neurodegenerative disorders 45 . Similarly, MRI imaging of endothelial adhesion molecules detects the inflammatory phenotype of brain vascular endothelium in the rodent brain and models of different brain diseases 150 , which could be extended and developed for the living human brain. Similar types of probes could be developed to interrogate RAGE-mediated Aβ vascular influx and/or LRP1mediated Aβ vascular efflux capacity. Longitudinal studies with high-field-strength 7T (or greater) magnets will provide improved sensitivity to detect early, subtle, regional changes in cerebrovascular dysfunction, which will confirm or amend the temporal course of biomarker abnormalities in AD and other neurodegenerative disorders. The advances in imaging will continue to establish new early vascular biomarkers in the living human brain, hopefully revealing untapped novel targets of disease-modifying therapeutics for multiple neurodegenerative disorders.
